AD 1208
Alternative Names: AD-1208Latest Information Update: 16 Jul 2024
At a glance
- Originator Avelos Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action MASTL protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 29 May 2024 Preclinical trials in Cancer in South Korea (PO), prior to May 2024
- 29 May 2024 Avelos Therapeutics plans to initiate clinical trials for Cancer in the second half of 2024
- 05 Apr 2024 Pharmacodynamics and adverse events data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research